Analyst Coverage

The following research analysts cover Destiny Pharma.

Mark Brewer, finnCap	+44(0)20 7220 0500
Andy Smith, Equity Development	+44(0)20 7065 2690
Karl Keegan, Singer Capital Markets	+44(0)20 7496 3187

Please click on links below to access coverage published:

	finnCap Analyst research from finnCap can be obtained by registering on the link above 19 July 2022 – Positive FDA feedback on pivotal US trial design 5 July 2022 – New clinical study with XF-73 in oral mucositis prevention
	Equity Development 19 July 2022 – Greater regulatory clarity given 5 July 2022 – A useful addition to XF-73’s profile
	Proactive Investors For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above
	VOX Markets For further commentary and interviews, please visit the Destiny Pharma page at Vox Markets on the link above